AU2019350356B9 - Arginase1 polypeptides - Google Patents

Arginase1 polypeptides

Info

Publication number
AU2019350356B9
AU2019350356B9 AU2019350356A AU2019350356A AU2019350356B9 AU 2019350356 B9 AU2019350356 B9 AU 2019350356B9 AU 2019350356 A AU2019350356 A AU 2019350356A AU 2019350356 A AU2019350356 A AU 2019350356A AU 2019350356 B9 AU2019350356 B9 AU 2019350356B9
Authority
AU
Australia
Prior art keywords
cells
arglong2
peptide
polypeptide
tnfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019350356A
Other languages
English (en)
Other versions
AU2019350356A8 (en
AU2019350356A1 (en
AU2019350356B2 (en
Inventor
Mads Hald Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Publication of AU2019350356A1 publication Critical patent/AU2019350356A1/en
Publication of AU2019350356A8 publication Critical patent/AU2019350356A8/en
Application granted granted Critical
Publication of AU2019350356B2 publication Critical patent/AU2019350356B2/en
Publication of AU2019350356B9 publication Critical patent/AU2019350356B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2019350356A 2018-09-24 2019-09-24 Arginase1 polypeptides Active AU2019350356B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1815549.9A GB201815549D0 (en) 2018-09-24 2018-09-24 Arginase1 polypeptides
GB1815549.9 2018-09-24
PCT/EP2019/075731 WO2020064744A1 (en) 2018-09-24 2019-09-24 Arginase1 polypeptides

Publications (4)

Publication Number Publication Date
AU2019350356A1 AU2019350356A1 (en) 2021-04-15
AU2019350356A8 AU2019350356A8 (en) 2021-05-27
AU2019350356B2 AU2019350356B2 (en) 2025-11-27
AU2019350356B9 true AU2019350356B9 (en) 2026-01-29

Family

ID=64024184

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019350356A Active AU2019350356B9 (en) 2018-09-24 2019-09-24 Arginase1 polypeptides

Country Status (12)

Country Link
US (2) US12194081B2 (https=)
EP (1) EP3856899A1 (https=)
JP (1) JP7624388B2 (https=)
KR (1) KR20210091696A (https=)
CN (1) CN112771159B (https=)
AU (1) AU2019350356B9 (https=)
CA (1) CA3113004A1 (https=)
GB (1) GB201815549D0 (https=)
IL (1) IL281762A (https=)
MX (1) MX2021003441A (https=)
SG (1) SG11202102378WA (https=)
WO (1) WO2020064744A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201818576D0 (en) 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
JP2025508840A (ja) 2022-02-24 2025-04-10 アイオー バイオテック エーピーエス アルギナーゼ２ワクチン

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018065563A1 (en) * 2016-10-07 2018-04-12 Herlev Hospital Immunogenic arginase peptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5780286A (en) 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
US20110111424A1 (en) 2001-06-21 2011-05-12 Cell Signaling Technology, Inc. Analysis of ubiquitinated polypeptides
US20030228583A1 (en) 2001-10-31 2003-12-11 Amacher David E. Biomarkers of liver response
CA2586048C (en) 2004-10-29 2014-03-11 Gregg A. Howe Protection against herbivores
PT3778885T (pt) 2008-10-31 2023-05-31 Aerase Inc Composições de arginases humanas modificadas e métodos para o tratamento do cancro
CN101781369A (zh) * 2009-01-20 2010-07-21 江苏先声药物研究有限公司 一种重组人精氨酸酶融合蛋白及其应用
ES2897635T3 (es) 2014-04-29 2022-03-02 Bio Cancer Treat International Ltd Métodos y composiciones para modular el sistema inmunológico con la arginasa I
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018065563A1 (en) * 2016-10-07 2018-04-12 Herlev Hospital Immunogenic arginase peptides

Also Published As

Publication number Publication date
US20220031818A1 (en) 2022-02-03
US20250205318A1 (en) 2025-06-26
GB201815549D0 (en) 2018-11-07
KR20210091696A (ko) 2021-07-22
CA3113004A1 (en) 2020-04-02
JP2022501046A (ja) 2022-01-06
CN112771159A (zh) 2021-05-07
AU2019350356A8 (en) 2021-05-27
EP3856899A1 (en) 2021-08-04
MX2021003441A (es) 2021-06-15
JP7624388B2 (ja) 2025-01-30
AU2019350356A1 (en) 2021-04-15
AU2019350356B2 (en) 2025-11-27
IL281762A (en) 2021-05-31
WO2020064744A1 (en) 2020-04-02
SG11202102378WA (en) 2021-04-29
CN112771159B (zh) 2025-02-11
US12194081B2 (en) 2025-01-14

Similar Documents

Publication Publication Date Title
US20250205318A1 (en) Arginase1 polypeptides
AU2020287902B2 (en) TGF-beta vaccine
US20250388674A1 (en) Immunogenic arginase 2 polypeptides
US20250161422A1 (en) Arginase 2 vaccine
EP4611788A1 (en) Tgf-beta-1 vaccine

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 35 , NO 15 , PAGE(S) 3405 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME MADS HALD ANDERSEN, APPLICATION NO. 2019350356, UNDER INID (71) CORRECT THE APPLICANT NAME TO IO BIOTECH APS.

SREP Specification republished
FGA Letters patent sealed or granted (standard patent)